Telmisartan, Ramipril, or Both in Patients at High Risk for Vascular Events | Zendy

The ONTARGET Investigators | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Telmisartan, Ramipril, or Both in Patients at High Risk for Vascular Events

Author(s) -

The ONTARGET Investigators

Publication year - 2008

Publication title -

new england journal of medicine

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 19.889

H-Index - 1030

eISSN - 1533-4406

pISSN - 0028-4793

DOI - 10.1056/nejmoa0801317

Subject(s) - ramipril , telmisartan , medicine , diabetes mellitus , ace inhibitor , angiotensin receptor blockers , heart failure , cardiology , angiotensin converting enzyme , vascular disease , pharmacology , endocrinology , blood pressure

In patients who have vascular disease or high-risk diabetes without heart failure, angiotensin-converting-enzyme (ACE) inhibitors reduce mortality and morbidity from cardiovascular causes, but the role of angiotensin-receptor blockers (ARBs) in such patients is unknown. We compared the ACE inhibitor ramipril, the ARB telmisartan, and the combination of the two drugs in patients with vascular disease or high-risk diabetes.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research